Alivus Life Sciences Reports Strong Q2 and H1 FY26 Unaudited Financial Results
Alivus Life Sciences reported significant growth in Q2 and H1 FY26, with revenue and profit rising substantially. The Board approved the unaudited financial results for the period ended September 30, 2025.
Positive financial results demonstrating significant growth in both revenue and profitability are key indicators for investors and can lead to increased investor confidence and potential stock price appreciation.
The company reported substantial increases in revenue from operations, total income, profit before tax, and profit for the period for both the quarter and half year ended September 30, 2025, compared to the previous year. This consistent growth across key financial metrics indicates strong performance.
* Alivus Life Sciences Limited's Board of Directors, at its meeting held on November 6, 2025, approved the unaudited financial results for the second quarter and half year ended September 30, 2025. * For the second quarter ended September 30, 2025: * Revenue from Operations increased to ₹5,879.80 million (₹587.98 crore) from ₹5,068.79 million (₹506.88 crore) in the corresponding quarter of the previous year. * Total Income rose to ₹6,027.00 million (₹602.70 crore) from ₹5,154.12 million (₹515.41 crore). * Profit Before Tax (PBT) significantly grew to ₹1,741.37 million (₹174.14 crore) from ₹1,274.56 million (₹127.46 crore). * Profit for the Period reached ₹1,300.26 million (₹130.03 crore) compared to ₹953.16 million (₹95.32 crore). * Basic Earnings per Share (EPS) stood at ₹10.60, up from ₹7.78. * For the half year ended September 30, 2025: * Revenue from Operations increased to ₹11,898.26 million (₹1,189.83 crore) from ₹10,954.95 million (₹1,095.50 crore) in the previous half year. * Total Income increased to ₹12,135.31 million (₹1,213.53 crore) from ₹11,095.21 million (₹1,109.52 crore). * PBT for the half year was ₹3,371.18 million (₹337.12 crore) compared to ₹2,776.94 million (₹277.69 crore). * Profit for the Period for the half year was ₹2,515.61 million (₹251.56 crore) compared to ₹2,067.99 million (₹206.80 crore). * Basic EPS for the half year was ₹20.51, up from ₹16.88. * The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 6, 2025. The Statutory Auditor, Walker Chandiok & Co. LLP, provided an unmodified conclusion on the limited review of the results. * The company identifies its sole reporting segment as Active Pharmaceutical Ingredient (API). * As of September 30, 2025, there are 6,00,631 options outstanding under the Employee Stock Option Plan 2021, convertible into an equivalent number of equity shares.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.